Retatrutide is a research peptide designed to activate GLP-1, GIP, and glucagon receptors, influencing appetite regulation, insulin signaling, and energy metabolism. This page is for educational purposes only.
| Category | Information |
|---|---|
| Type | Triple incretin receptor agonist |
| Targets | GLP-1, GIP, glucagon receptors |
| Half-life | ~6 days (estimated from trials) |
| Administration | Subcutaneous injection |
| Primary research focus | Obesity and metabolic disease |
| Status | Investigational — not FDA-approved |
Retatrutide is a synthetic peptide classified as a triple incretin receptor agonist. It belongs to a growing family of incretin-based therapies that target hormonal pathways involved in metabolism, appetite, and blood glucose regulation. Unlike earlier compounds that activate one or two receptors, retatrutide was engineered to engage all three key incretin-related targets simultaneously.
The development of incretin therapies represents a significant area of metabolic research. GLP-1 receptor agonists like semaglutide were the first generation, followed by dual agonists like tirzepatide. Retatrutide extends this approach by adding glucagon receptor activation, which researchers hypothesize may amplify energy expenditure and fat metabolism beyond what dual agonists achieve.
As an investigational compound, retatrutide is not available by prescription and has not received regulatory approval. For a deeper look at the peptide itself, see the retatrutide peptide guide.
GLP-1 (glucagon-like peptide-1) receptor activation is the most well-studied component of incretin-based therapies. When retatrutide binds to GLP-1 receptors, it promotes insulin secretion in response to food intake, slows gastric emptying, and reduces appetite signaling in the brain. These effects have been consistently demonstrated across the GLP-1 agonist class and contribute to reduced caloric intake.
Slower gastric emptying means food stays in the stomach longer, contributing to feelings of fullness. Central appetite suppression occurs through hypothalamic signaling pathways that regulate hunger and satiety.
GIP (glucose-dependent insulinotropic polypeptide) receptor activation adds a second metabolic signaling pathway. GIP plays a role in insulin regulation and energy balance, though its effects are more nuanced than GLP-1. In combination with GLP-1 activation, GIP receptor engagement appears to enhance overall metabolic signaling.
Research suggests that dual GLP-1/GIP activation, as seen with tirzepatide, produces stronger metabolic outcomes than GLP-1 activation alone. Retatrutide builds on this dual foundation by adding a third target.
The glucagon receptor component is what distinguishes retatrutide from other incretin therapies. Glucagon receptor activation is associated with increased metabolic rate, enhanced fat oxidation, and thermogenesis—the process by which the body generates heat from stored energy.
This third pathway is hypothesized to contribute to retatrutide's higher weight reduction percentages in clinical trials compared to dual-agonist compounds. By increasing energy expenditure while simultaneously reducing appetite, the triple-agonist approach targets both sides of the energy balance equation.
| Study / Phase | Duration | Key Outcome |
|---|---|---|
| Phase 2 (2023) | 24 weeks | Dose-dependent weight reduction up to ~24% |
| Phase 2 (2023) | 48 weeks | Sustained metabolic improvements |
| Phase 3 (ongoing) | 52+ weeks | Long-term efficacy under evaluation |
These figures come from published clinical trial data. Individual outcomes vary depending on dosing, adherence, baseline health, and other factors. Phase 3 trials are ongoing and may yield different long-term results. None of these findings constitute a guarantee of individual outcomes.
| Time | Commonly Reported Effects |
|---|---|
| Week 1–4 | Appetite changes, mild GI adjustment |
| Week 4–8 | Noticeable appetite reduction |
| Week 8–12 | Measurable metabolic changes |
| Week 12–24 | Significant weight reduction trends |
| Week 24+ | Sustained effects observed in trials |
For a more detailed week-by-week breakdown, see the full retatrutide results timeline.
| Peptide | Receptors | Status | Key Difference |
|---|---|---|---|
| Semaglutide | GLP-1 | FDA-approved | Single target, longest track record |
| Tirzepatide | GLP-1 + GIP | FDA-approved | Dual target, approved for weight |
| Retatrutide | GLP-1 + GIP + Glucagon | Investigational | Triple target, highest weight loss in trials |